德纳维制药(DVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

DVAX 德纳维制药

盘后交易 12-09 16:49:14 EST

10.89

-0.08

-0.73%

盘后10.77

-0.12-1.10%

16:45 EST

最高11.11	最低10.86	成交量119.87万
今开10.97	昨收10.97	日振幅2.28%
总市值12.79亿	流通市值10.77亿	总股本1.17亿
成交额1,311万	换手率1.21%	流通股本9,891万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"DVAX","market":"US","secType":"STK","nameCN":"德纳维制药","latestPrice":10.89,"timestamp":1765314000000,"preClose":10.97,"halted":0,"volume":1198706,"hourTrading":{"tag":"盘后","latestPrice":10.77,"preClose":10.89,"latestTime":"16:45 EST","volume":32561,"amount":354589.062073,"timestamp":1765316733959},"delay":0,"floatShares":98912259,"shares":117424968,"eps":-0.359451,"marketStatus":"盘后交易","change":-0.08,"latestTime":"12-09 16:49:14 EST","open":10.97,"high":11.11,"low":10.86,"amount":13112093.52924,"amplitude":0.022789,"askPrice":11.48,"askSize":80,"bidPrice":10.23,"bidSize":80,"shortable":3,"etf":0,"ttmEps":-0.359451,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1765328400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1077166800000,"exchange":"NASDAQ","adjPreClose":10.97,"preHourTrading":{"tag":"盘前","latestPrice":10.89,"preClose":10.97,"latestTime":"08:33 EST","volume":224,"amount":2459.299808,"timestamp":1765287229309},"postHourTrading":{"tag":"盘后","latestPrice":10.77,"preClose":10.89,"latestTime":"16:45 EST","volume":32561,"amount":354589.062073,"timestamp":1765316733959},"volumeRatio":0.765481,"impliedVol":0.3897,"impliedVolPercentile":0.708},"requestUrl":"/m/hq/s/DVAX","defaultTab":"news","newsList":[{"id":"1186165748","title":"美股疫苗股大跌，FDA 官员提及新冠疫苗与年轻男性心脏疾病有关联","url":"https://stock-news.laohu8.com/highlight/detail?id=1186165748","media":"老虎资讯综合","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186165748?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:25","pubTimestamp":1764635137,"startTime":"0","endTime":"0","summary":"在疫情期间，Prasad 因反对疫苗强制措施以及对新冠疫苗引发心肌炎风险的关注而在网上获得追随者。其他研究则发现，新冠感染导致心肌炎的风险高于接种疫苗。辉瑞和 BioNTech 共同研发了新冠疫苗 Comirnaty。两家公司均研发并销售新冠 mRNA 疫苗。这并非 Prasad 首次推动与 mRNA 新冠疫苗相关的变更。这位 FDA 官员还呼吁为疫苗临床试验设定不同的终点指标。","market":"us","thumbnail":"https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f5a0c542474fbfdd95db309645c9c3a7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"美股疫苗股大跌，FDA 官员提及新冠疫苗与年轻男性心脏疾病有关联","news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA","BNTX","PFE","DVAX"],"gpt_icon":1},{"id":"2581753005","title":"德纳维制药盘中异动 股价大涨5.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581753005","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581753005?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:31","pubTimestamp":1762439471,"startTime":"0","endTime":"0","summary":"北京时间2025年11月06日22时31分，德纳维制药股票出现异动，股价急速拉升5.53%。截至发稿，该股报10.87美元/股，成交量6.755万股，换手率0.06%，振幅2.33%。德纳维制药股票所在的制药行业中，整体涨幅为0.06%。德纳维制药公司简介：Dynavax Technologies Corp 是一家生物制药公司，专注于通过 Toll 样受体刺激来利用人体先天和适应性免疫反应的力量。消息层面，截至22时31分，《威廉博莱维持德纳维制药买入评级》资讯为影响德纳维制药的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110622311197586029&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110622311197586029&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DVAX","BK4139"],"gpt_icon":0},{"id":"1198474248","title":"德纳维制药 - Z-1018 显示与 Shingrix 类似的反应并具良好耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1198474248","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198474248?lang=zh_cn&edition=full","pubTime":"2025-10-22 04:02","pubTimestamp":1761076928,"startTime":"0","endTime":"0","summary":"德纳维制药 - Z-1018 显示与 Shingrix 类似的反应并具良好耐受性","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVAX","BK4139"],"gpt_icon":0},{"id":"1149499484","title":"德纳维制药发布2025年Idweek上带状疱疹疫苗候选药物第1/2阶段试验第1部分的积极顶线数据，并宣布启动试验第2部分","url":"https://stock-news.laohu8.com/highlight/detail?id=1149499484","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149499484?lang=zh_cn&edition=full","pubTime":"2025-10-22 04:01","pubTimestamp":1761076871,"startTime":"0","endTime":"0","summary":"德纳维制药发布2025年Idweek上带状疱疹疫苗候选药物第1/2阶段试验第1部分的积极顶线数据，并宣布启动试验第2部分。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DVAX"],"gpt_icon":0},{"id":"1174829488","title":"德纳维制药盘前涨7.7%，研究显示其带状疱疹疫苗免疫反应与葛兰素史克产品相当","url":"https://stock-news.laohu8.com/highlight/detail?id=1174829488","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174829488?lang=zh_cn&edition=full","pubTime":"2025-08-21 20:10","pubTimestamp":1755778244,"startTime":"0","endTime":"0","summary":"德纳维制药盘前涨7.7%，研究显示其带状疱疹疫苗免疫反应与葛兰素史克产品相当","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1046248800.SGD","IE00BQJZX424.USD","LU1302929846.USD","LU1064927863.SGD","IE0034235071.USD","LU1400636657.SGD","IE00BWDBJ516.SGD","LU0575583348.USD","LU1228905037.USD","LU0971552830.HKD","BK5011","LU1645745479.HKD","LU1202635105.USD","LU0306806265.USD","LU0321505439.SGD","LU0306807586.USD","LU0289739699.SGD","BK4139","LU0985481810.HKD","DVAX","LU1481599808.USD","LU1487256676.USD","LU1670756490.USD","LU0211331839.USD","LU1015430645.USD","GSK.UK","LU0971552673.USD","LU1228905540.USD","LU1481600234.SGD","LU0225771236.USD","LU1400636574.HKD","LU1098665638.USD","LU0203345920.USD","LU0321505868.SGD","LU0203347892.USD","LU0109981661.USD","LU0058720904.USD","LU0545562505.USD","LU1035777561.USD","LU0225284248.USD","LU1400636491.USD"],"gpt_icon":0},{"id":"1183570094","title":"德纳维制药宣布带状疱疹疫苗1/2期临床试验取得积极顶线结果，支持其同类最佳疫苗潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1183570094","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183570094?lang=zh_cn&edition=full","pubTime":"2025-08-21 20:02","pubTimestamp":1755777768,"startTime":"0","endTime":"0","summary":"德纳维制药宣布其带状疱疹疫苗1/2期临床试验取得积极的顶线结果，这些数据支持该疫苗具备同类最佳产品的潜在特性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVAX","BK4139"],"gpt_icon":0},{"id":"1115331889","title":"德纳维制药：针对70岁及以上成人的Z-1018最佳剂量1/2期试验第二部分预计下半年启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1115331889","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115331889?lang=zh_cn&edition=full","pubTime":"2025-08-21 20:00","pubTimestamp":1755777624,"startTime":"0","endTime":"0","summary":"德纳维制药宣布，该公司针对70岁及以上成人群体的Z-1018药物1/2期临床试验第二部分预计将在下半年启动。此次试验将采用最佳剂量进行测试。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVAX","BK4139"],"gpt_icon":0},{"id":"1124972261","title":"德纳维制药Z-1018试验显示注射后不良反应低于Shingrix","url":"https://stock-news.laohu8.com/highlight/detail?id=1124972261","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124972261?lang=zh_cn&edition=full","pubTime":"2025-08-21 20:00","pubTimestamp":1755777624,"startTime":"0","endTime":"0","summary":"德纳维制药宣布，在Z-1018临床试验中，其疫苗产品显示出比Shingrix更低的预期局部和全身注射后不良反应。这一试验结果表明，德纳维制药的疫苗候选产品在安全性方面可能具有优势，注射后引发的局部反应和全身性反应均较Shingrix为低。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DVAX"],"gpt_icon":0},{"id":"1159423422","title":"Dynavax Technologies：1/2期临床试验第一阶段显示Z-1018耐受性良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1159423422","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159423422?lang=zh_cn&edition=full","pubTime":"2025-08-21 20:00","pubTimestamp":1755777617,"startTime":"0","endTime":"0","summary":"Dynavax Technologies：1/2期临床试验第一阶段显示Z-1018耐受性良好，具有良好的安全性表现","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVAX","BK4139"],"gpt_icon":0},{"id":"1134215720","title":"异动解读 | 德纳维制药盘中大涨9.04%，超预期季度业绩提振投资者信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1134215720","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134215720?lang=zh_cn&edition=full","pubTime":"2025-08-08 21:43","pubTimestamp":1754660624,"startTime":"0","endTime":"0","summary":"周五盘中，德纳维制药股价大涨9.04%，引发市场广泛关注。这一显著涨幅主要源于公司发布的超预期第二季度财报，展现出强劲的业务增长势头。根据公司最新发布的财报显示，截至2025年6月30日的第二季度，德纳维制药调整后每股收益达到14美分，不仅显著高于去年同期的8美分，还超过了分析师平均预期的11美分。值得注意的是，尽管德纳维制药今年以来股价累计下跌12.4%，但分析师对公司前景保持乐观态度。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DVAX"],"gpt_icon":0},{"id":"2513475690","title":"德纳维制药2024财年实现净利润27.31百万美元，同比增加527.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513475690","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513475690?lang=zh_cn&edition=full","pubTime":"2025-02-24 00:01","pubTimestamp":1740326471,"startTime":"0","endTime":"0","summary":"2月24日，德纳维制药公布财报，公告显示公司2024财年净利润为27.31百万美元，同比增加527.39%；其中营业收入为2.77亿美元，同比增加19.40%，每股基本收益为0.21美元。从资产负债表来看，德纳维制药总负债3.89亿美元，其中短期债务4.18百万美元，资产负债比为2.54，流动比率为0.11。机构评级：截至2025年2月24日，当前有4家机构对德纳维制药目标价做出预测，其中目标均价为25.25美元，其中最低目标价为12.00美元，最高目标价为33.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000141abd9c7e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000141abd9c7e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DVAX"],"gpt_icon":0},{"id":"2513303296","title":"德纳维制药盘中异动 早盘股价大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513303296","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513303296?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:37","pubTimestamp":1740148645,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时37分，德纳维制药股票出现异动，股价大幅上涨5.03%。截至发稿，该股报14.00美元/股，成交量12.7185万股，换手率0.10%，振幅3.66%。机构评级方面，在所有5家参与评级的机构中，80%的券商给予买入建议，20%的券商给予卖出建议，无券商给予持有建议。德纳维制药股票所在的制药行业中，整体涨幅为0.32%。德纳维制药公司简介：Dynavax Technologies Corp 是一家生物制药公司，专注于通过 Toll 样受体刺激来利用人体先天和适应性免疫反应的力量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223726a24eb1e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223726a24eb1e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DVAX","BK4139"],"gpt_icon":0},{"id":"1106935012","title":"Dynavax Technologies 第四季度 GAAP 每股收益 $0.05 超过预期 $0.04，销售额 $72.03M 未达预期 $72.70M","url":"https://stock-news.laohu8.com/highlight/detail?id=1106935012","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106935012?lang=zh_cn&edition=full","pubTime":"2025-02-21 05:14","pubTimestamp":1740086064,"startTime":"0","endTime":"0","summary":"Dynavax Technologies  报告季度每股收益 $0.05，比分析师一致预期的 $0.04 超出 25%。公司报告季度销售额 $72.03百万，未达到分析师一致预期的 $72.70百万，相差 0.92%。与去年同期的 $55.60百万销售额相比，此次增长了 29.56%。以上内容来自Benzinga Earnings专栏，原文如下：Dynavax Technologies  reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.04 by 25 percent.  The company reported quarterly sales of $72.03 million which missed the analyst consensus estimate of $72.70 million by 0.92 percent.  This is a 29.56 percent increase over sales of $55.60 m","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Dynavax Technologies 第四季度 GAAP 每股收益 $0.05 超过预期 $0.04，销售额 $72.03M 未达预期 $72.70M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVAX"],"gpt_icon":0},{"id":"2510131886","title":"带状疱疹和乙肝疫苗需求前景不明朗 高盛看跌德纳维制药(DVAX.US)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510131886","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510131886?lang=zh_cn&edition=full","pubTime":"2025-02-12 11:45","pubTimestamp":1739331951,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛将德纳维制药的评级从“中性”下调至“卖出”，并将目标价从15美元下调至12美元，原因是其带状疱疹疫苗和乙肝疫苗的需求前景不明朗。据了解，葛兰素史克的带状疱疹疫苗Shingrix预充式注射器有望提升接种便捷性，这种产品的上市申请已获美国FDA和欧洲药品管理局受理。德纳维制药预计将于2月20日公布第四季度财报。截至周二美股收盘，德纳维制药跌3.79%，报12.7美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1248741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4516","DVAX","IE00B19Z3B42.SGD","BK4552","BK4585","LU2237438978.USD","BK4550","BK4139","LU2237443622.USD","LU2237443978.SGD","IE0034235188.USD","IE00BFXG1179.USD","IE0004086264.USD","LU2237443465.HKD","BK4588","LU0106831901.USD","LU2237443549.SGD","BK4504","LU2237443895.HKD","IE0002270589.USD","IE00B19Z3581.USD","LU1791807156.HKD","LU2237443382.USD","IE0004091025.USD","BK4533","BK4127","IE00BSNM7G36.USD","LU1668664300.SGD"],"gpt_icon":0},{"id":"2510852380","title":"德纳维制药盘中异动 股价大跌8.94%报12.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510852380","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510852380?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:31","pubTimestamp":1739284278,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时31分，德纳维制药股票出现异动，股价急速跳水8.94%。截至发稿，该股报12.02美元/股，成交量14.3749万股，换手率0.11%，振幅0.15%。最近的财报数据显示，该股实现营业收入80.63百万美元，净利润17.59百万美元，每股收益0.13美元，毛利67.55百万美元，市盈率80.13倍。机构评级方面，在所有6家参与评级的机构中，83%的券商给予买入建议，17%的券商给予持有建议，无券商给予卖出建议。德纳维制药股票所在的制药行业中，整体涨幅为0.01%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223118abcb05b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223118abcb05b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DVAX","BK4139"],"gpt_icon":0},{"id":"2484986079","title":"德纳维制药盘中异动 股价大跌5.00%报11.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484986079","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484986079?lang=zh_cn&edition=full","pubTime":"2024-11-19 04:47","pubTimestamp":1731962830,"startTime":"0","endTime":"0","summary":"北京时间2024年11月19日04时47分，德纳维制药股票出现波动，股价急速下跌5.00%。截至发稿，该股报11.60美元/股，成交量166.22万股，换手率1.26%，振幅6.10%。最近的财报数据显示，该股实现营业收入80.63百万美元，净利润17.59百万美元，每股收益0.13美元，毛利67.55百万美元，市盈率77.43倍。德纳维制药股票所在的制药行业中，整体跌幅为1.55%。德纳维制药公司简介：Dynavax Technologies Corp 是一家生物制药公司，专注于通过 Toll 样受体刺激来利用人体先天和适应性免疫反应的力量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111904471198e43567&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111904471198e43567&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","DVAX"],"gpt_icon":0},{"id":"2484510942","title":"德纳维制药2024财年第三财季实现净利润17.59百万美元，同比增加23.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484510942","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484510942?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:03","pubTimestamp":1731772983,"startTime":"0","endTime":"0","summary":"11月17日，德纳维制药公布财报，公告显示公司2024财年第三财季净利润为17.59百万美元，同比增加23.09%；其中营业收入为80.63百万美元，同比增加16.00%，每股基本收益为0.13美元。从资产负债表来看，德纳维制药总负债3.81亿美元，其中短期债务4.42百万美元，资产负债比为2.79，流动比率为0.14。机构评级：截至2024年11月17日，当前有5家机构对德纳维制药目标价做出预测，其中目标均价为23.80美元，其中最低目标价为15.00美元，最高目标价为29.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000400abc79069&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000400abc79069&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DVAX"],"gpt_icon":0},{"id":"2483101370","title":"德纳维制药盘中异动 快速下挫5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483101370","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483101370?lang=zh_cn&edition=full","pubTime":"2024-11-15 22:46","pubTimestamp":1731682011,"startTime":"0","endTime":"0","summary":"北京时间2024年11月15日22时46分，德纳维制药股票出现波动，股价大幅下挫5.00%。截至发稿，该股报12.72美元/股，成交量28.8417万股，换手率0.22%，振幅4.48%。机构评级方面，在所有6家参与评级的机构中，83%的券商给予买入建议，17%的券商给予持有建议，无券商给予卖出建议。德纳维制药股票所在的制药行业中，整体跌幅为2.03%。德纳维制药公司简介：Dynavax Technologies Corp 是一家生物制药公司，专注于通过 Toll 样受体刺激来利用人体先天和适应性免疫反应的力量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115224652971a6da7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115224652971a6da7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DVAX","BK4139"],"gpt_icon":0},{"id":"1174668754","title":"异动解读 | 德纳维制药公司因回购计划推升 股价盘中大涨6.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174668754","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174668754?lang=zh_cn&edition=full","pubTime":"2024-11-12 02:01","pubTimestamp":1731348081,"startTime":"0","endTime":"0","summary":"据路透社报道,2024年11月11日,医药股德纳维制药公司 股价盘中大涨6.53%,最高达到13.84美元,成交量显著增加。根据消息,德纳维制药预计将最初回购约610万股,占交易的80%,最终结算将于明年第一季度完成。此次回购计划是该公司早前宣布2亿美元回购计划的一部分。德纳维制药是一家总部位于加州的生物制药公司,专注于利用先天性免疫反应和适应性免疫反应。目前公司市值约18亿美元,流通股1.315亿股,机构普遍给予\"买入\"评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DVAX"],"gpt_icon":0},{"id":"2482385607","title":"德纳维制药盘中异动 大幅上涨5.00%报13.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482385607","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482385607?lang=zh_cn&edition=full","pubTime":"2024-11-11 22:31","pubTimestamp":1731335515,"startTime":"0","endTime":"0","summary":"北京时间2024年11月11日22时31分，德纳维制药股票出现异动，股价急速拉升5.00%。截至发稿，该股报13.66美元/股，成交量37.5476万股，换手率0.29%，振幅1.84%。德纳维制药股票所在的制药行业中，整体跌幅为0.35%。其相关个股中，Evotec Se、Sonoma Pharmaceuticals, Inc.、施贵宝涨幅较大，Sonoma Pharmaceuticals, Inc.、Sunshine Biopharma Inc.、Akanda Corp.较为活跃，换手率分别为2.86%、0.68%、0.64%，振幅较大的相关个股有晖致、Rockwell Medical, Inc.、德纳维制药，振幅分别为101.23%、4.74%、4.07%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111223155abb6616f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111223155abb6616f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","DVAX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dynavax.com","stockEarnings":[{"period":"1week","weight":0.0243},{"period":"1month","weight":0.0129},{"period":"3month","weight":0.1058},{"period":"6month","weight":0.0776},{"period":"1year","weight":-0.1463},{"period":"ytd","weight":-0.141}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":0.0189},{"period":"3month","weight":0.0512},{"period":"6month","weight":0.1368},{"period":"1year","weight":0.1247},{"period":"ytd","weight":0.1664}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Dynavax Technologies Corporation于1996年8月29日在加利福尼亚州双螺旋结构公司的名下注册成立，1999年9月更名为 Dynavax 技术公司。该公司于2000年在特拉华州重组。该公司是一家完全集成的生物制药公司，专注于通过Toll样受体（“TLR”）刺激来利用人体先天和适应性免疫反应的力量。他们的第一个商业产品HEPLISAV-B（乙型肝炎疫苗（重组型），佐剂化）于2017年11月获得美国食品和药物管理局（“FDA”）批准用于预防所有已知乙型肝炎亚型引起的感染病毒在18岁以上的成人。他们于2018年1月开始商业运送HEPLISAV-B。他们的开发工作主要集中在刺激先天性免疫反应，与其他免疫调节剂联合治疗癌症。他们的主要研究免疫肿瘤产品是SD-101，目前正在进行阶段2临床研究评估，DV281进行阶段1安全性研究。","yearOnYearQuotes":[{"month":1,"riseRate":0.52381,"avgChangeRate":0.002211},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.027901},{"month":3,"riseRate":0.409091,"avgChangeRate":-0.007392},{"month":4,"riseRate":0.318182,"avgChangeRate":-0.006058},{"month":5,"riseRate":0.5,"avgChangeRate":0.022333},{"month":6,"riseRate":0.5,"avgChangeRate":0.023462},{"month":7,"riseRate":0.545455,"avgChangeRate":0.057705},{"month":8,"riseRate":0.454545,"avgChangeRate":0.040776},{"month":9,"riseRate":0.409091,"avgChangeRate":-0.02771},{"month":10,"riseRate":0.5,"avgChangeRate":-0.003182},{"month":11,"riseRate":0.590909,"avgChangeRate":0.044257},{"month":12,"riseRate":0.5,"avgChangeRate":0.127066}],"exchange":"NASDAQ","name":"德纳维制药","nameEN":"Dynavax"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"德纳维制药(DVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供德纳维制药(DVAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"德纳维制药,DVAX,德纳维制药股票,德纳维制药股票老虎,德纳维制药股票老虎国际,德纳维制药行情,德纳维制药股票行情,德纳维制药股价,德纳维制药股市,德纳维制药股票价格,德纳维制药股票交易,德纳维制药股票购买,德纳维制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"德纳维制药(DVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供德纳维制药(DVAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}